The University of Southampton
University of Southampton Institutional Repository

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons
Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons
Objective: dinutuximab beta (dB) immunotherapy is used as maintenance treatment for relapsed/refractory neuroblastoma (NBL); however, comparative studies directly comparing dB with no dB therapy in this setting are lacking. This study aimed to indirectly compare dB (with or without interleukin-2) with no immunotherapy in patients with relapsed NBL.

Methods: three studies of dB (APN311-202, APN311-304, and APN311-303) with individual patient data, along with two historical control cohorts (INBR and R1) were included. Both unadjusted (naïve) and population-adjusted comparisons of overall survival (OS) were performed, with adjustment conducted using inverse probability or odds weighting. Harmonized inclusion criteria were applied across all study populations. The adjusted comparison used the propensity score reweighting to balance the cohorts based on key baseline prognostic factors.

Results: the base-case unadjusted indirect comparison revealed that dB (with or without IL-2) significantly prolonged OS compared to historical controls not treated with dB (hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.31– 0.79; p<0.001). Similarly, in the adjusted comparison, dB significantly prolonged OS compared to historical controls (HR, 0.53; 95% CI, 0.35; 0.79, p=0.002). All sensitivity unadjusted and adjusted comparisons supported the results of the base-case analysis.

Conclusion: dinutuximab beta significantly prolonged OS compared to historical control cohorts not treated with dB in both unadjusted and adjusted indirect comparisons.
2234-943X
Lode, Holger N.
c6482d76-8235-40b9-adbd-1d3cae4ac2c3
Holko, Przemysław
947844b8-0376-4dca-bde2-034c18d15748
Wieczorek, Aleksandra
d3e4a0a9-4c94-47f6-85b6-432250f5c6a0
Sladowska, Katarzyna
d966e12e-1747-4f5f-9174-949e1c727711
Siebert, Nikolai
6b70ee04-d122-4b19-a561-ddfa846ebd33
Valteau-Couanet, Dominique
bc187ffa-e252-45d4-adf0-9df6965b995d
Garaventa, Alberto
c88dee5a-d6de-4855-8ac2-091f95727d15
Cañete, Adela
e6e3a4b0-1e50-44ff-a3e2-9514961c707c
Anderson, John
013b526f-687b-40d0-8f4c-6020d08022eb
Yaniv, Isaac
835d1ba8-2aef-4cae-ba16-2acd30cdfb14
Ash, Shifra
61248c74-800c-44a1-a905-74a10d32e200
Moreno, Lucas
f8620b45-f3e2-4eb5-952e-e94ae0d9bf19
Gray, Juliet
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Luksch, Roberto
b6decc11-7892-4a57-9f8c-3ccc3ee99db8
Laureys, Genevieve
f98a8561-258d-4bf5-861b-9f72d313a566
Owens, Cormac
7e0e9bb1-fddc-4915-bda5-2fa7bf448a2d
Manzitti, Carla
fa621140-a3dd-4e58-8c71-59fd75101b0b
Troschke-Meurer, Sascha
72de5b00-4da8-42a8-b277-0627010f3667
Kawalec, Paweł
1dc12ea0-d53f-4c3f-8772-4f1924f11d95
Ladenstein, Ruth L.
646da3c0-c69d-4dde-9f9d-e3cd41bd0ec9
Lode, Holger N.
c6482d76-8235-40b9-adbd-1d3cae4ac2c3
Holko, Przemysław
947844b8-0376-4dca-bde2-034c18d15748
Wieczorek, Aleksandra
d3e4a0a9-4c94-47f6-85b6-432250f5c6a0
Sladowska, Katarzyna
d966e12e-1747-4f5f-9174-949e1c727711
Siebert, Nikolai
6b70ee04-d122-4b19-a561-ddfa846ebd33
Valteau-Couanet, Dominique
bc187ffa-e252-45d4-adf0-9df6965b995d
Garaventa, Alberto
c88dee5a-d6de-4855-8ac2-091f95727d15
Cañete, Adela
e6e3a4b0-1e50-44ff-a3e2-9514961c707c
Anderson, John
013b526f-687b-40d0-8f4c-6020d08022eb
Yaniv, Isaac
835d1ba8-2aef-4cae-ba16-2acd30cdfb14
Ash, Shifra
61248c74-800c-44a1-a905-74a10d32e200
Moreno, Lucas
f8620b45-f3e2-4eb5-952e-e94ae0d9bf19
Gray, Juliet
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Luksch, Roberto
b6decc11-7892-4a57-9f8c-3ccc3ee99db8
Laureys, Genevieve
f98a8561-258d-4bf5-861b-9f72d313a566
Owens, Cormac
7e0e9bb1-fddc-4915-bda5-2fa7bf448a2d
Manzitti, Carla
fa621140-a3dd-4e58-8c71-59fd75101b0b
Troschke-Meurer, Sascha
72de5b00-4da8-42a8-b277-0627010f3667
Kawalec, Paweł
1dc12ea0-d53f-4c3f-8772-4f1924f11d95
Ladenstein, Ruth L.
646da3c0-c69d-4dde-9f9d-e3cd41bd0ec9

Lode, Holger N., Holko, Przemysław, Wieczorek, Aleksandra, Sladowska, Katarzyna, Siebert, Nikolai, Valteau-Couanet, Dominique, Garaventa, Alberto, Cañete, Adela, Anderson, John, Yaniv, Isaac, Ash, Shifra, Moreno, Lucas, Gray, Juliet, Luksch, Roberto, Laureys, Genevieve, Owens, Cormac, Manzitti, Carla, Troschke-Meurer, Sascha, Kawalec, Paweł and Ladenstein, Ruth L. (2026) Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons. Frontiers in Oncology, 15. (doi:10.3389/fonc.2025.1736165).

Record type: Article

Abstract

Objective: dinutuximab beta (dB) immunotherapy is used as maintenance treatment for relapsed/refractory neuroblastoma (NBL); however, comparative studies directly comparing dB with no dB therapy in this setting are lacking. This study aimed to indirectly compare dB (with or without interleukin-2) with no immunotherapy in patients with relapsed NBL.

Methods: three studies of dB (APN311-202, APN311-304, and APN311-303) with individual patient data, along with two historical control cohorts (INBR and R1) were included. Both unadjusted (naïve) and population-adjusted comparisons of overall survival (OS) were performed, with adjustment conducted using inverse probability or odds weighting. Harmonized inclusion criteria were applied across all study populations. The adjusted comparison used the propensity score reweighting to balance the cohorts based on key baseline prognostic factors.

Results: the base-case unadjusted indirect comparison revealed that dB (with or without IL-2) significantly prolonged OS compared to historical controls not treated with dB (hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.31– 0.79; p<0.001). Similarly, in the adjusted comparison, dB significantly prolonged OS compared to historical controls (HR, 0.53; 95% CI, 0.35; 0.79, p=0.002). All sensitivity unadjusted and adjusted comparisons supported the results of the base-case analysis.

Conclusion: dinutuximab beta significantly prolonged OS compared to historical control cohorts not treated with dB in both unadjusted and adjusted indirect comparisons.

Other
1736165_Manuscript - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (2MB)
Text
fonc-15-1736165 - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)

More information

Accepted/In Press date: 22 December 2025
e-pub ahead of print date: 22 January 2026

Identifiers

Local EPrints ID: 508971
URI: http://eprints.soton.ac.uk/id/eprint/508971
ISSN: 2234-943X
PURE UUID: 2bf6b9bd-5a52-42d5-8b1d-72ff90421d49
ORCID for Juliet Gray: ORCID iD orcid.org/0000-0002-5652-4722

Catalogue record

Date deposited: 09 Feb 2026 17:40
Last modified: 07 Mar 2026 02:56

Export record

Altmetrics

Contributors

Author: Holger N. Lode
Author: Przemysław Holko
Author: Aleksandra Wieczorek
Author: Katarzyna Sladowska
Author: Nikolai Siebert
Author: Dominique Valteau-Couanet
Author: Alberto Garaventa
Author: Adela Cañete
Author: John Anderson
Author: Isaac Yaniv
Author: Shifra Ash
Author: Lucas Moreno
Author: Juliet Gray ORCID iD
Author: Roberto Luksch
Author: Genevieve Laureys
Author: Cormac Owens
Author: Carla Manzitti
Author: Sascha Troschke-Meurer
Author: Paweł Kawalec
Author: Ruth L. Ladenstein

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×